Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer

Amanda P. Struckhoff, Robert Bittman, Matthew E. Burow, Sanda Clejan, Steven Elliott, Timothy Hammond, Yan Tang and Barbara S. Beckman
Journal of Pharmacology and Experimental Therapeutics May 2004, 309 (2) 523-532; DOI: https://doi.org/10.1124/jpet.103.062760
Amanda P. Struckhoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Bittman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew E. Burow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanda Clejan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Elliott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Hammond
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Tang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara S. Beckman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recent evidence suggests a role for aberrant ceramide levels in the pathogenesis of cancer and chemoresistance and indicates that manipulation of tumor ceramide levels may be a useful strategy in the fight against breast cancer. This study demonstrates that alterations in the degree and position of unsaturation of bonds in the sphingoid backbone of d-erythro-N-octanoyl-sphingosine (Cer) affect the antiproliferative ability of ceramide analogs in breast cancer cells. The most potent analog of Cer we tested is (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-diol (4,6-diene-Cer), which contains an additional trans double bond at C(6)-C(7) of the sphingoid backbone. 4,6-Diene-Cer exhibited higher potency than Cer in tumor necrosis factor (TNF)-α-resistant (IC50 of 11.3 versus 32.9 μM) and TNF-α-sensitive (IC50 of 13.7 versus 37.7 μM) MCF-7 cells. 4,6-Diene-Cer was also more potent than Cer in inducing cell death in MDA-MB-231 and NCI/ADR-RES breast cancer cell lines (IC50 of 3.7 versus 11.3 μM, and 24.1 versus 86.9 μM, respectively). 4,6-Diene-Cer caused a prolonged elevation of intracellular ceramide levels in MCF-7 cells, which may contribute to its enhanced cytotoxicity. Furthermore, treatment of MCF-7 cells with Cer or 4,6-diene-Cer resulted in induction of apoptosis by 8 h via the mitochondrial pathway, as demonstrated by release of cytochrome c, loss of membrane asymmetry (measured by Annexin V staining), and a decrease in the mitochondrial membrane potential. Importantly, both Cer and 4,6-diene-Cer displayed selectivity toward transformed breast cells over nontransformed breast epithelial cells. These data suggest that these and other novel ceramide analogs represent potential therapeutic agents in breast cancer treatment.

Footnotes

  • This work was supported by Department of Defense Breast Cancer Research Grant DAMD17-01-1-0432 (to A.P.S), National Institutes of Health Grant 5 MOI RR05096-10 (to S.C. with GCRC), and National Institutes of Health Grant HL16660 (to R.B.).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • DOI: 10.1124/jpet.103.062760.

  • ABBREVIATIONS: Cer, (2S,3R)-N-octanoyl-sphingosine; DH-Cer, (2S,3R)-N-octanoyl-4,5-dihydrosphingosine; 4,6-diene-Cer, (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-diol; 4,6-diene-7-Ph-Cer, (2S,3R)-(4E,6E)-2-octanoylamido-7-phenylheptadiene-1,3-diol; 6-ene-Cer, (2S,3R)-(6E)-2-octanoylamidooctadecene-1,3-diol; 6-OH-Cer, (2S,3R,6S)-(4E)-2-octanoylamidooctadecene-1,3,6-triol; 6-OH-4-yne-Cer, (2S,3R,6S)-2-octanoylamido-4-octadecyne-1,3,6-triol; TNF, tumor necrosis factor; hTERT, human telomerase; DMEM, Dulbecco's modified Eagle's medium; HME, human mammary epithelial; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; PI, propidium iodide; ΔΨm, mitochondrial membrane potential; JC-1, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide; DAG, diacylglycerol; HPLC, high-performance liquid chromatography.

    • Received November 11, 2003.
    • Accepted January 21, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 309 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 309, Issue 2
1 May 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer

Amanda P. Struckhoff, Robert Bittman, Matthew E. Burow, Sanda Clejan, Steven Elliott, Timothy Hammond, Yan Tang and Barbara S. Beckman
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 523-532; DOI: https://doi.org/10.1124/jpet.103.062760

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer

Amanda P. Struckhoff, Robert Bittman, Matthew E. Burow, Sanda Clejan, Steven Elliott, Timothy Hammond, Yan Tang and Barbara S. Beckman
Journal of Pharmacology and Experimental Therapeutics May 1, 2004, 309 (2) 523-532; DOI: https://doi.org/10.1124/jpet.103.062760
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Time-to-Event Analysis of Paclitaxel Peripheral Neuropathy
  • Lysosomal Biogenesis and Hydroxychloroquine Disposition
  • MEK for ALK-Positive Lung Cancer
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics